BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24185260)

  • 1. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interactions between hERG potassium channel and blockers.
    Du L; Li M; You Q
    Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
    Taboureau O; Jørgensen FS
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations.
    Recanatini M; Cavalli A; Masetti M
    ChemMedChem; 2008 Apr; 3(4):523-35. PubMed ID: 18224703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
    Ridley JM; Milnes JT; Hancox JC; Witchel HJ
    J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of temperature-induced hERG channel blockade variation by drugs.
    Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
    J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine-learning technique, QSAR and molecular dynamics for hERG-drug interactions.
    Das NR; Sharma T; Toropov AA; Toropova AP; Tripathi MK; Achary PGR
    J Biomol Struct Dyn; 2023; 41(23):13766-13791. PubMed ID: 37021352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
    Guo J; Gang H; Zhang S
    J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.